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ABSTRACT:
Glioblastoma is the most common malignant primary brain tumor. Temozolomide 
(TMZ) is the standard chemotherapeutic agent for this disease. However, intrinsic 
and acquired TMZ-resistance represents a major obstacle for this therapy. In order 
to identify factors involved in TMZ-resistance, we engineered different TMZ-resistant 
glioblastoma cell lines. Gene expression analysis demonstrated that EFEMP1, an 
extracellular matrix protein, is associated with TMZ-resistant phenotype. Silencing 
of EFEMP1 in glioblastoma cells resulted in decreased cell survival following TMZ 
treatment,  whereas  overexpression  caused  TMZ-resistance.  EFEMP1  acts  via 
multiple signaling pathways, including γ-secretase-mediated activation of the Notch 
pathway. We show that inhibition of γ-secretase by RO4929097 causes at least 
partial sensitization of glioblastoma cells to temozolomide in vitro and in vivo. In 
addition, we show that EFEMP1 expression levels correlate with survival in TMZ-
treated glioblastoma patients. Altogether our results suggest EFEMP1 as a potential 
therapeutic target to overcome TMZ-resistance in glioblastoma.
INTRODUCTION
Glioblastoma is the most common malignant 
primary brain tumor in humans. Outcome for glioblastoma 
patients is dismal, and carries a median survival of only 
14 months [1]. Standard treatment consists of surgery 
(if possible), followed by radiotherapy and adjuvant 
temozolomide (TMZ) chemotherapy [1, 2]. Although 
the addition of TMZ to radiotherapy has resulted in an 
overall increase in survival of glioblastoma patients, 
therapy still fails in almost all glioblastoma patients due to 
incomplete tumor resection, and/or the apparent resistance 
of tumor cells to irradiation and TMZ. Some tumors are 
insensitive to TMZ already at diagnosis, whereas others 
may develop acquired TMZ-resistance during treatment. 
Therefore, TMZ-resistance represents a major obstacle in 
the treatment of this disease. 
The cytotoxic effect of TMZ is mainly mediated 
through induction of the DNA adduct O6-methylguanine 
(O6M-G) resulting in activation of the mismatch repair 
(MMR) system, induction of DNA double strand breaks, 
and subsequent cell death [3, 4]. The alkylation of the O6 
position of guanine can be counteracted by the MGMT 
protein (O6-methylguanine DNA methyltransferase). It is 
widely accepted that hypermethylation of the promoter of 
the MGMT gene in the tumor tissue can predict sensitivity 
to TMZ [5–7], since hypermethylation prevents the 
expression of MGMT thereby sensitizing the cells to TMZ Oncotarget 364 www.impactjournals.com/oncotarget
[8, 9]. The highly relevant role of MGMT in response 
to TMZ is confirmed by the increased sensitivity when 
combining TMZ with the competitive MGMT inhibitor 
O6-benzylguanine [10–12]. Also the MMR status can 
be important for TMZ sensitivity, as a functional MMR 
mechanism is required to induce double strand breaks, 
and subsequent cell cycle arrest and apoptosis [3, 4, 13]. 
Defects in MMR have been suggested to be involved 
especially in acquired TMZ-resistance [14–16]. Besides 
the canonical MGMT and MMR TMZ-resistance 
mechanisms it is likely that non-canonical mechanisms can 
also contribute to TMZ-resistance. Further insight into the 
underlying mechanisms of non-canonical TMZ-resistance 
mechanisms may not only allow for better prediction of 
treatment response, and thus to individualized therapy, 
but may also provide targets for counteracting TMZ-
resistance.
EFEMP1 (Fibulin-3) is an extracellular matrix 
protein involved in tumor progression in several types 
of cancer [17–20]. In glioblastoma, EFEMP1 has been 
reported to stimulate tumor growth, invasion of tumor 
cells, and resistance to apoptosis [21, 22]. EFEMP1 can 
exert these tumor promoting effects through activation of 
the Notch signaling pathway [22], although EFEMP1 was 
also reported to activate EGFR  and the downstream AKT/
PI3K/mTor, and MAPK pathways [19, 23]. Activation 
of the Notch cascade has been previously implicated in 
TMZ-resistance in glioblastoma, and plays an essential 
role in determining cell fates such as differentiation, 
proliferation, and apoptosis [24–26]. Here we identify 
by gene expression profiling of both TMZ-sensitive and 
non-canonical TMZ-resistant glioblastoma cell lines that 
expression of EFEMP1 is associated with a TMZ-resistant 
phenotype. Furthermore, we show that EFEMP1-mediated 
TMZ-resistance is regulated – at least partly – through the 
Notch pathway. 
RESULTS
EFEMP1 is overexpressed in TMZ-resistant 
glioblastoma cells
In order to develop TMZ-resistant glioblastoma 
cells, we treated Hs683, U87, and LNZ308 glioblastoma 
cells twice a week with 33 µM TMZ for several weeks, 
resulting in two independent stable TMZ-resistant 
subclones for each glioblastoma cell line. The TMZ 
sensitivity was determined by automated cell counting at 
four days post-TMZ treatment (Fig. 1A). The IC50 values 
of the resistant glioblastoma subclones showed >2-fold 
increase in TMZ-resistance compared to the parental cell 
lines (Supplementary Table S1). These cell lines were 
characterized for MGMT methylation and MMR status 
to assess canonical TMZ-resistance mechanisms, but no 
significant differences were observed between the parental 
cell line and the resistant subclones (Supplementary 
Table S1), suggesting that a non-canonical TMZ-
resistance mechanism was acquired by these cells, and 
– consequently - resulting in a useful tool to study non-
canonical TMZ-resistance. 
In order to determine which non-canonical 
mechanisms are responsible for the observed TMZ-
resistance, we isolated RNA from the parental glioblastoma 
cells (designated WT) and the two independent TMZ-
resistant subclones (designated R1 and R2). We performed 
gene expression array analysis and a significance analysis 
of microarrays (SAM analysis) using a false discovery rate 
of <10%. We identified transcripts that were differentially 
expressed between the WT and R1/R2 glioblastoma cells 
of each individual glioblastoma cell line and overlapping 
transcripts among the different resistant glioblastoma cells 
(Fig. 1B). Genes that were differentially expressed in at 
least five out of six TMZ-resistant glioblastoma subclones 
are depicted in heatmap format (Fig. 1C). The top-6 
transcripts overexpressed in all six resistant subclones 
were validated by qRT-PCR (Fig. 1D). EFEMP1 emerged 
as the most differentially expressed mRNA in all three 
glioblastoma cell lines with >2-fold (p<0.05) increased 
EFEMP1 expression in the TMZ-resistant glioblastoma 
subclones (Fig. 1D). Moreover, by comparing the IC50 
values of the WT, R1, and R2 glioblastoma cell lines to the 
corresponding EFEMP1 expression levels, we identified a 
positive correlation between these two variables (r2=0.56, 
p=0.021) (Supplementary Fig. S1), suggesting that 
EFEMP1 expression is associated with a TMZ-resistant 
phenotype.
EFEMP1 induces non-canonical TMZ-resistance 
in glioblastoma cells
To determine whether EFEMP1 can act as a sole 
effector of non-canonical TMZ-resistance in glioblastoma 
cells, we overexpressed EFEMP1 in Hs683 cells. We 
compared the EFEMP1 expression levels of Hs683-
EFEMP1 cells to Hs683-WT and Hs683-R1 cells by 
qRT-PCR and showed a >3-fold upregulation of EFEMP1 
in Hs683-EFEMP1 cells compared to Hs683-WT cells 
(Fig. 2A). We then treated Hs683-EFEMP1, Hs683-
WT, and Hs683-R1 cells with TMZ, and measured cell 
viability four days later. The overexpression of EFEMP1 
resulted in a significant increase in resistance to TMZ 
as compared to the parental Hs683 cells (Fig. 2B). The 
resistance effect of EFEMP1 overexpression in Hs683 
cells was confirmed by clonogenic assays (Figs. 2C and 
D), which showed a significant increase in clonogenic 
survival of Hs683-EFEMP1 cells as compared to Hs683-
WT cells. Conversely, >80% knock down (p<0.05) of 
EFEMP1 by siEFEMP1 as demonstrated by qRT-PCR 
(Fig. 2E), resulted in reduced cell survival of TMZ-Oncotarget 365 www.impactjournals.com/oncotarget
resistant Hs683-R1 and Hs683-WT cells, as assessed 
by clonogenic analysis after TMZ treatment (Fig. 2F). 
However, significant effects of EFEMP1 knock down 
on cell survival were also observed in the absence of 
TMZ treatment, indicating a dependence of these cells 
on EFEMP1 expression for survival, as was previously 
described [22].
EFEMP1 induces Notch signaling in glioblastoma 
cells
EFEMP1 as part of the extracellular matrix can 
exert its cellular signaling function via multiple pathways, 
including the EGFR and Notch signaling cascades (Fig. 
3A) [19, 22]. In order to determine whether EFEMP1 
overexpression resulted in the activation of the Notch 
signaling pathway in the TMZ-resistant glioblastoma cells, 
we first assessed the expression of the Notch-induced 
genes HES1 and HEY1 by qRT-PCR (Fig. 3B). We show 
that HES1 and/or HEY1 were >2-fold overexpressed 
(p<0.05) in the TMZ-resistant cells, except for U87-R1. 
Subsequently, we determined whether blocking of the 
Notch pathway could overcome the EFEMP1-mediated 
resistance to TMZ, by treating the Hs683-WT and 
Hs683-R1 glioblastoma cells that demonstrated high 
expression of HES1/HEY1 with TMZ and the γ-secretase 
inhibitor (GSI) DAPT (Fig. 3C). Treatment of Hs683-R1 
with DAPT in the absence of TMZ resulted in a 20% 
decrease in cell viability (p<0.05), which was not observed 
in Hs683-WT cells. Importantly, in combination with 
TMZ, treatment with DAPT resulted in enhanced cell 
kill as compared to TMZ alone (Fig. 3C). Subsequently, 
we assessed the inhibitory effects of the clinically 
available GSIs RO4929097, BMS-708163, LY450139, 
and MK-0752 on the Notch pathway by determining 
HES1 expression after GSI treatment (Fig. 3D). At 
Figure 1: Identification of EFEMP1 as differentially expressed transcript in TMZ-resistant glioblastoma cells. A, 
Hs683, U87, and LNZ308 glioblastoma cells (WT) and TMZ-resistant subclones (R1 and R2) were analyzed for TMZ sensitivity by 
automated cell counting at four days after TMZ treatment. B, number of differentially expressed transcripts overlapping between resistant 
subclones R1 and R2 of each individual glioblastoma cell line (left) and number of overlapping transcripts among the resistant glioblastoma 
subclones (right). C, transcripts that were differentially expressed in at least five out of six TMZ-resistant glioblastoma subclones are shown 
in heatmap format. D, the top-6 transcripts overexpressed in all six resistant subclones were validated by qRT-PCR. Shown are averages, 
error bars indicate SD. *p<0.05 t test.
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the concentration used, treatment with RO4929097 
resulted in the largest reduction (approximately 75%, 
p<0.05) of HES1 expression in Hs683-R1 glioblastoma 
cells. Therefore, we selected RO4929097 for combined 
treatment with TMZ on Hs683-WT and Hs683-R1 cells. 
Similar as for treatment with DAPT (Fig. 3C), RO4929097 
treatment alone resulted in decreased cell viability 
and in combination with TMZ, RO4929097 treatment 
significantly enhanced cell kill compared to TMZ alone in 
the TMZ-resistant Hs683-R1 cells (Fig. 3E). In addition, 
we demonstrated similar effects of combined treatment 
with TMZ and RO4929097 on U87-WT and U87-R1 cells 
(Fig. 4A) and on primary glioblastoma cell lines (Fig. 4B). 
These primary glioblastoma cells were characterized for 
their MGMT promoter methylation status and MGMT 
protein expression (Fig. 4C). We showed that treatment 
with RO4929097 potentiated the TMZ effect on U87-R1 
and the primary glioblastoma cell lines, including on 
MGG23 cells that were the only primary glioblastoma cells 
included to have an unmethylated MGMT promoter and 
high expression of MGMT. Altogether these data suggest 
that GSIs can decrease Notch signaling in glioblastoma 
cells and potentiate the TMZ effect on glioblastoma 
cells that acquired EFEMP1-mediated TMZ-resistance. 
Moreover, these results support previous reports on TMZ-
sensitizing effects of GSIs in glioblastoma cells [24–26].  
Effect of RO4929097 in combination with TMZ 
treatment on orthotopic Hs683 glioblastoma in 
vivo 
In order to assess whether inhibition of the Notch 
pathway could potentiate TMZ treatment in orthotopic 
glioblastoma in vivo, Hs683 cells were transduced with 
a lentiviral vector encoding the Fluc bioluminescence 
Figure 2: EFEMP1 induces TMZ-resistance in glioblastoma cells. A, EFEMP1 mRNA expression levels of Hs683-EFEMP1, 
Hs683-WT and Hs683-R1 cells as determined by qRT-PCR. B, Hs683-EFEMP1, Hs683-WT, and Hs683-R1 cells treated with TMZ and 
cell viability measured after four days. C, representative images of the effect of EFEMP1 overexpression in Hs683 cells on TMZ sensitivity 
as measured by clonogenic assays. Size bar, 5 mm. D, quantification of C. E, knock down of EFEMP1 using siEFEMP1 or siCTRL 
in Hs683-R1 cells 48 hrs after transfection as determined by qRT-PCR. F, cell viability of cells depicted in E upon TMZ treatment as 
determined by a clonogenic assay. Shown are averages, error bars indicate SD. *p<0.05 t test.
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reporter generating Hs683-Fluc. Next, Hs683-Fluc 
glioblastoma cells were injected into the striatum of nude 
mice (n=24). Six days post-implantation the luciferase 
signal was measured and mice were randomized into 
four treatment groups (i.e. CTRL; TMZ; RO4929097; 
TMZ+RO4929097; n=6 per group). Directly after 
randomization, mice were treated with TMZ and/or 
RO4929097 for five consecutive days. At day 1 and 5 
of treatment, mice were treated with only RO4929097 
while on day 2, 3, and 4 mice were treated with both TMZ 
and RO4929097 or corresponding vehicles. We assessed 
glioblastoma growth over time by Fluc bioluminescence 
imaging. Fluc activity demonstrated that treatment with 
TMZ+RO4929097  significantly  reduced  Hs683-Fluc 
tumor growth in vivo compared to tumor growth in non-
treated mice (p=0.023) (Figs. 5A-C), although under 
these devastating conditions we were not able to measure 
significant effects on survival (survival 18±6 days after 
injection of the Hs683-Fluc cells). These results suggest 
that inhibitors of the Notch pathway may sensitize 
glioblastoma cells to TMZ in vivo. 
EFEMP1 expression correlates to TMZ treatment 
efficacy and survival in glioblastoma patients 
In order to determine the clinical relevance of 
EFEMP1 in glioblastoma, we determined the EFEMP1 
expression levels in multiple publicly available 
glioblastoma datasets [27–34] using the microarray 
analysis and visualization platform R2 (http://r2.amc.nl) 
and showed a significant overexpression of EFEMP1 in 
glioblastoma tissues as compared to non-neoplastic brain 
tissue (Fig. 6A). Next we analyzed whether EFEMP1 
expression is a predictive biomarker candidate for the 
efficacy  of  TMZ  treatment  in  glioblastoma  patients. 
Therefore, we analyzed overall survival of glioblastoma 
patients treated with or without TMZ (TMZ-treated 
n=82, not TMZ-treated n=70, www.rembrandt.org) in 
correlation with EFEMP1 expression. When EFEMP1 
expression was high (>2-fold increased compared to 
Figure 3: EFEMP1 induces Notch signaling in glioblastoma cells. A, schematic overview of EFEMP1 activation of EGFR [19] 
and Notch [22] signaling. MAGP-1/2, CCN3, YB-1, DLL, and Jagged are alternative Notch ligands [46–48, 50, 51]. B, mRNA expression 
of the Notch-induced genes HES1 and HEY1 in the TMZ-resistant glioblastoma cells as determined by qRT-PCR. C, cell viability analysis 
of Hs683-WT and Hs683-R1 glioblastoma cells four days after treatment with TMZ and DAPT (25 µM). D, HES1 expression after 
treatment with clinically available GSIs RO4929097, BMS-708163, LY450139, and MK-0752 as determined by qRT-PCR. E, cell viability 
analysis of Hs683-WT and Hs683-R1 four days after treatment with TMZ and RO4929097 (50 µM).  Shown are averages, error bars 
indicate SD. *p<0.05 t test.
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non-neoplastic tissue, red and green line), patients had a 
worse prognosis in the TMZ-treated group (Fig. 6B, upper 
panel), while no difference in survival was observed in 
the non-TMZ treated group (Fig. 6B, lower panel). 
Correspondingly, patients with low EFEMP1 expression 
(<2-fold increased compared to non-neoplastic tissue, 
blue and purple line) had a relatively good prognosis 
when treated with TMZ (Fig. 6B). Thus, EFEMP1 is a 
significant biomarker candidate for survival in the TMZ-
treated group (p=0.044), but not in glioblastoma patients 
that are not treated with TMZ (p=0.46). These results 
suggest that EFEMP1 overexpression is predictive for the 
resistance to TMZ in glioblastoma patients. Finally, we 
determined if EFEMP1 expression levels had increased 
in patient samples upon progression of disease following 
TMZ treatment. Therefore, EFEMP1 mRNA expression 
was determined by qRT-PCR in relapse samples and 
compared to their expression in the corresponding 
samples at diagnosis. Although we had a limited number 
of samples, a clear trend could be observed towards an 
increased expression of EFEMP1 in glioblastoma samples 
at the time of progression (Fig. 6C), suggesting that 
EFEMP1 could be used as a marker for tumor progression 
after TMZ treatment.
DISCUSSION
Glioblastoma is the most common malignant 
primary brain tumor with a median survival rate of 14 
months. While adding TMZ to radiotherapy results in 
an overall increase in survival of glioblastoma patients, 
almost all patients die. Multiple TMZ-resistance 
mechanisms have been demonstrated, including 
activity of MGMT [8, 9], MMR [14, 15], but also BER 
resistance mechanisms [35–37], and drug efflux pumps 
[38]. However, it is unlikely that these mechanisms are 
responsible for all TMZ-resistance observed. Here we 
attempted to determine non-canonical factors that may 
influence the efficacy of TMZ in glioblastoma. Using 
gene expression analysis of both TMZ-sensitive and 
TMZ-resistant glioblastoma cell lines, we demonstrated 
that overexpression of EFEMP1 is associated with a TMZ-
resistant phenotype in glioblastoma cells. 
EFEMP1 (Fibulin-3) belongs to the family of fibulin 
proteins, which are secreted proteins that integrate into 
the extracellular matrix. These proteins form anchoring 
structures that were reported to regulate cell proliferation, 
adhesion, and migration [39, 40], and several fibulins 
have been associated with the development of solid 
Figure  4:  RO4929097  and  TMZ  treatment  of 
glioblastoma  cells  in  vitro.  A, cell viability analysis of 
U87-WT and U87-R1 cells four days after treatment with 
RO4929097 (30 µM) and TMZ (100 µM). B, similar as A for a 
panel of primary glioblastoma cell lines. C, MGMT methylation 
status and MGMT protein expression of the individual primary 
glioblastoma cell lines used in B. Shown are averages, error bars 
indicate SD. *p<0.05 t test.
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Figure 5: RO4929097 and TMZ treatment of orthotopic 
Hs683-Fluc glioblastoma in vivo. A, mean Fluc activity 
values of different treatment groups measured over time using 
a  CCD  camera.  Arrows  indicate  five  consecutive  treatment 
days starting at day six after Hs683-Fluc cells injection in the 
striatum of nude mice. B, Fluc activity values of individual 
mice per treatment group at the start of treatment (day 6) and 
six  days  after  treatment  had  finished.  C,  representative  Fluc 
bioluminescence images of treatment groups at different time 
points after injection of cells (day 0). Shown are averages, error 
bars indicate SEM. The p values indicate two-sided t-test.Oncotarget 369 www.impactjournals.com/oncotarget
tumors [39, 40]. EFEMP1 is not significantly expressed 
in normal brain [21, 27, 41, 42], however, it is highly 
expressed in high-grade gliomas, where it promotes tumor 
growth and invasion [21, 22]. Glioblastomas consist of 
different molecular subtypes, i.e. classical, mesenchymal, 
neural, and proneural glioblastoma subtypes [43]. It was 
previously described that EFEMP1 is a mesenchymal-
related gene highly expressed in primary brain tumors [21, 
44]. In addition, EFEMP1 levels were higher in gliomas 
of the mesenchymal subtype compared to the proneural 
subtype which have poor overall survival compared to the 
other subtypes [22]. It would be of interest to determine 
whether EFEMP1 expression correlates with TMZ 
resistance and survival in this glioblastoma subclass. 
In contrast, a recent report [45] identified patients with 
glioblastomas of the proneural subtype enriched as 
responders to Notch inhibition via γ-secretase inhibitors. 
These proneural glioblastomas were characterized by high 
Notch pathway activation. Yet unknown is whether these 
patients also have increased levels of EFEMP1 expression. 
Here we demonstrate a significant role for EFEMP1 
in TMZ-resistance of glioblastoma cells. At this point, 
however, inhibitors of EFEMP1 are not yet available. 
EFEMP1 can act on multiple pathways, including EGFR 
[19], and the downstream pathways MAPK [19], and 
AKT/PI3K/mTor [19, 20, 23]. Moreover, EFEMP1 has 
been identified as an activator of Notch signaling which 
results in increased invasion, tumor cell self-renewal, 
chemoresistance, and glioblastoma growth [22]. It was 
postulated that EFEMP1 can serve as a target that restricts 
anti-invasive and chemosensitizing effects to tumor cells 
without the pleiotropic effects of current pharmacologic 
inhibitors of Notch [22]. In our study, we show that 
EFEMP1 overexpression activates the Notch pathway 
in TMZ-resistant glioblastoma, while interference with 
the Notch pathway conveys partial sensitivity to TMZ-
resistant glioblastoma cells. It should be noted that Notch 
signaling can also be activated in an EFEMP1-independent 
manner. Therefore, it remains to be determined what the 
exact contribution of EFEMP1 to Notch signaling is in 
TMZ-resistant glioblastoma cells in relation to other 
factors that can induce Notch signaling, including MAGP-
1/2, CCN3, YB-1, DLL, and Jagged [46–51]. Furthermore, 
as mentioned above, EFEMP1 can act on other pathways, 
including EGFR which could also convey resistance to 
glioblastoma cells and could explain that only partial 
Figure 6: EFEMP1 expression correlates to TMZ treatment efficacy and survival in glioblastoma patients. A, EFEMP1 
expression levels in multiple publicly available glioblastoma datasets as visualized by using R2 (R2.amc.nl). Glioblastoma datasets (red) 
[28–34] were compared to normal brain (grey) [27]. [Number of patients] included in dataset are shown. B, survival of glioblastoma patients 
with high- (red and green), or low (blue and purple) EFEMP1 expression was plotted for TMZ-treated (n=82, upper panel) or non-treated 
(n=70, lower panel) patients (www.rembrandt.org). C, EFEMP1 mRNA expression levels in patient samples upon clinical progression 
following TMZ treatment (post-TMZ), compared to matching samples biopsied at diagnosis (pre-TMZ). Numbers (#) represent individual 
glioblastoma patients. Expression levels were normalized to expression in non-neoplastic brain tissue. Shown are averages, error bars 
indicate SD. *p<0.05 t test.
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sensitization to TMZ treatment is observed upon Notch 
inhibition. Considering this, it would be of interest to 
examine the potential involvement of these pathways in 
providing TMZ-resistance.
Although we were able to demonstrate significant 
effects of RO4929097 on TMZ sensitivity in vitro, and as 
measured by a reduction of orthotopic Hs683-Fluc tumor 
growth in mice in vivo, we were not able to measure 
significant  effects  on  survival  between  the  different 
treatment groups, which we mainly attribute due to the 
relatively large variation in survival upon growth of these 
devastating orthotopic Hs683-Fluc tumors in the brains of 
mice. Supportive of our results are the previous reports on 
Notch pathway inhibitors synergizing with TMZ treatment 
in other glioblastoma models [24–26]. And, importantly, 
the first clinical trial of the GSI RO4929097 with TMZ 
treatment in glioblastoma patients has been initiated 
(http://clinicaltrials.gov/show/NCT01119599). It would 
be of interest to determine whether EFEMP1 expression 
levels correlate with the effect of GSIs and TMZ on patient 
survival in this patient group. Moreover, blood plasma-
based assays are available to quantify secreted EFEMP1 
expression levels [52]. Further research is needed to 
determine whether EFEMP1 level in glioblastoma tissue 
and/or in blood could serve as a stratification marker for 
the treatment of patients with TMZ and/or GSIs. 
In conclusion, we provide evidence for a role of 
EFEMP1 in TMZ-resistance in glioblastoma. Inhibition 
of EFEMP1 and/or its downstream signaling components 
may be a potential therapeutic venue for the sensitization 
of glioblastoma cells to TMZ.
MATERIALS AND METHODS
Cells
Human glioblastoma cell lines Hs683, U87, and 
LNZ308 were cultured in DMEM (PAA Laboratories, 
GmbH, Pasching, Austria) supplemented with 10% fetal 
bovine serum (FBS) (PAA Laboratories, GmbH, Pasching, 
Austria), and 1 mg/ml penicillin-streptomycin (both 
PAA Laboratories, GmbH, Pasching, Austria) at 37°C 
and 5% CO2 in a humidified incubator. TMZ (Schering 
Plough, Kenilworth, NJ, USA) was dissolved in dimethyl 
sulfoxide (DMSO) to prepare a stock concentration of 150 
mM which was further diluted in cell culture medium to 
the working concentration. To generate TMZ-resistant cell 
lines, parental cells were treated twice a week in duplicate 
with a clinically relevant concentration of TMZ (33 µM). 
Exposure to TMZ was continued for multiple weeks (10-
18 weeks), until two individual resistant subclones were 
generated of each parental glioblastoma cell line. TMZ-
resistant cells were regularly challenged with 33 µM TMZ 
to maintain the resistant phenotype. Passage controls 
which were not treated with TMZ were cultured in parallel 
to use as controls for further analysis. To generate Hs683 
cells overexpressing EFEMP1, cells were transfected with 
an EFEMP1-overexpression construct kindly provided by 
Dr. M.S. Viapiano (The Ohio State University Medical 
Center and James Comprehensive Cancer Center, 
Columbus, OH, USA). Transfected glioblastoma cells 
were selected using 250 µg/ml of Zeocin Selection 
Reagent (Invitrogen, Carlsbad, CA, USA). For in vivo 
experiments, Hs683 cells were stably transduced with a 
lentivirus vector encoding firefly luciferase (Fluc) [53] 
to establish Hs683-Fluc cells. Primary glioblastoma 
cells, MGG4, MGG6, MGG8, and MGG23 were kindly 
provided by Hiroaki Wakimoto (Massachusetts General 
Hospital, Boston, MA, USA), and cultured as previously 
described [54]. The cells used in this study were not 
authenticated.
Gene expression profiling
Gene  expression  profiling  was  performed  at  the 
VUmc array core facility as described elsewhere [55, 56]. 
Briefly, RNA samples were Cy3- or Cy5-labeled using the 
Agilent Low RNA Input Linear Amplification Kit Plus, 
according to the manufacturer’s protocol. Subsequently, 
equal amounts (825 ng) of the Cy3 and Cy5 labeled 
samples were hybridized to Agilent 4×44K Whole Human 
GE arrays (Agilent), according to the manufacturer’s 
instructions. Samples derived from each individual 
glioblastoma cell line (both parental cell line and resistant 
subclones) were hybridized on a single slide. Slides were 
scanned using an Agilent Microarray scanner (G2565BA). 
Image analysis was performed using feature extraction 
software version 9.5 (Agilent Technologies). The Agilent 
GE2-v5_95 protocol was applied using default settings. 
Array normalization was performed with R-package 
Limma within the Bioconductor software. The microarray 
data have been deposited in NCBI’s Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo), Series 
Accession Number GSE53014.
qRT-PCR
Quantitive RT-PCR (qRT-PCR) analysis was used 
to determine the relative expression levels of EFEMP1, 
HES1, HEY1, and GAPDH mRNA. Total RNA from cell 
lines was isolated using TRIzol RNA isolation protocol 
(Invitrogen, Carlsbad, CA, USA) and total RNA from 
paraffin-embedded  glioblastoma  tissue  was  isolated 
using the RecoverAllTM Total Nucleic Acid Isolation Kit 
(Ambion, USA). Equal amounts of RNA were converted 
into cDNA using Omniscript kit (Qiagen, Hilden, 
Germany). Subsequently, qRT-PCR was performed 
with primers designed using Primer-Blast (NCBI) and 
manufactured by Invitrogen. The Ct values were used to Oncotarget 371 www.impactjournals.com/oncotarget
calculate the relative fold difference in mRNA levels. The 
data were normalized to GAPDH expression levels. 
Cell viability/survival assays
Cells were plated in 96-well plates and treated the 
subsequent day with increasing concentrations of TMZ 
and/or  the  γ-secretase  inhibitors  RO4929097,  DAPT, 
BMS-708163, LY450139, MK-0752 (SelleckChem, 
Houston, TX, USA). Four days after treatment, cells were 
fixed  with  3.7%  formaldehyde  and  DNA  was  stained 
with DAPI diluted in PBS (0.3 µg/ml). Cell number was 
assessed by counting the number of DAPI-stained cells 
using the Acumen Ex3 laser scanning cytometer (TTP 
LabTech, Royston, UK). Clonogenic assay was performed 
by plating single cells in 6-well plates. Three different 
cell dilutions (each in duplicate) were used per plate. 
For siRNA experiments, cells were cultured in a 6-well 
plate, transfected after 24 hrs with 66 nM of siEFEMP1 or 
siCTRL using lipofectamine 2000 (Invitrogen, Carlsbad, 
CA, USA), and plated as single cells subsequent day in 
three different cell dilutions. The next day, cells were 
treated with different drug concentrations. After 11-14 
days, colonies were washed with PBS, fixed with 3.7% 
formaldehyde, stained with Giemsa staining (1:10 in demi 
water), washed with water to remove the excess of Giemsa, 
and air dried. The number of colonies was determined by 
marking the stained colonies containing ≥50 cells using 
light microscopy. The survival fraction was determined 
by normalizing the number of colonies formed in the 
treatment condition to the number of colonies formed 
in the control condition [number of colonies formed / 
(number of cells plated x plating efficiency)]. Plating 
efficiency is defined as the percentage of cells plated that 
actually formed colonies in the control group. 
In vivo experiments
All animal studies were approved by the institutional 
ethical committee on animal experiments of the VU 
University (Amsterdam, The Netherlands). Six-weeks old 
female athymic nude mice (Harlan Laboratories, Horst, 
The Netherlands) were kept under specific-pathogen free 
conditions in air-filtered cages and received water and 
food ad libitum. Five µl containing 5x105 Hs683-Fluc 
cells was stereotactically injected into the striatum of 
nude mice (coordinates from bregma: -2.0 mm X, +0.5 
mm Y, -3.0 mm Z). Tumor size was monitored by Fluc 
bioluminescence imaging twice per week. At six days post-
injection of cells, mice were divided into four treatment 
groups (n=6 per group). The control group received 
intraperitoneal (i.p.) injection of 200 µl saline (TMZ-
vehicle), and/or per os (p.o.) injection of 200 µl 0.5% 
methylcellulose in sterile water (RO4929097-vehicle). 
TMZ-only treated group received 10 mg/kg TMZ i.p. and 
vehicle p.o., while the RO4929097-treated group received 
30 mg/kg RO4929097 p.o. and vehicle i.p.. The combined 
treatment group was injected with the same concentration 
of TMZ i.p. and RO4929097 orally. Mice were treated 
once daily for five consecutive days with RO4929097 or 
vehicle and on day 2, 3, and 4 with TMZ or vehicle. Mice 
were sacrificed after the humane endpoints were reached 
via sedation using isoflurane followed by i.p. injection 
of Euthasol. To assess significant differences between 
treatment groups, mice with Fluc bioluminescence values 
within each treatment group outside the mean ±2 x SD 
range were excluded from further analysis.
Statistical analysis
Difference in biological properties between treated 
and untreated cells was analysed using two-sided Student’s 
t-test. The p values <0.05 were considered statistically 
significant. SAM analysis (false discovery rate <10%) 
was used to determine significantly differential expressed 
genes in the gene expression microarray data [57]. 
Pearson’s correlation was used to determine association 
between IC50 values and EFEMP1 mRNA expression. 
Survival curves were compared by log-rank test.
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